Unknown

Dataset Information

0

Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations.


ABSTRACT: Glioblastoma is an aggressive disease characterized by moderate initial response rates to first-line radiation-chemotherapy intervention followed by low poor response rates to second-line intervention. This article discusses novel strategic platforms for the development of radiation-investigational agent combination clinical trials for primary and recurrent glioblastoma in a NCI-NCTN settings with simultaneous analysis of challenges in the drug development process.

SUBMITTER: Kunos CA 

PROVIDER: S-EPMC5709276 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations.

Kunos Charles A CA   Galanis Evanthia E   Buchsbaum Jeffrey J   Shi Qian Q   Strauss Lewis C LC   Coleman C Norman CN   Ahmed Mansoor M MM  

Journal of neuro-oncology 20170530 3


Glioblastoma is an aggressive disease characterized by moderate initial response rates to first-line radiation-chemotherapy intervention followed by low poor response rates to second-line intervention. This article discusses novel strategic platforms for the development of radiation-investigational agent combination clinical trials for primary and recurrent glioblastoma in a NCI-NCTN settings with simultaneous analysis of challenges in the drug development process. ...[more]

Similar Datasets

| S-EPMC10062405 | biostudies-literature
| S-EPMC9884437 | biostudies-literature
| S-EPMC8698904 | biostudies-literature
| S-EPMC7565291 | biostudies-literature
| S-EPMC6294341 | biostudies-literature
| S-EPMC8158457 | biostudies-literature
| S-EPMC8488228 | biostudies-literature
| S-EPMC8192997 | biostudies-literature
| S-EPMC7658017 | biostudies-literature
| S-EPMC7982586 | biostudies-literature